Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY Personalized medicine Pub Date : 2023-07-01 Epub Date: 2023-09-11 DOI:10.2217/pme-2023-0023
Gábor Kovács, Dávid Nagy, László Szilberhorn, Tamás Zelei, Zsolt Gaál, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten-van Mölken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Balázs Nagy
{"title":"Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.","authors":"Gábor Kovács,&nbsp;Dávid Nagy,&nbsp;László Szilberhorn,&nbsp;Tamás Zelei,&nbsp;Zsolt Gaál,&nbsp;Heleen Vellekoop,&nbsp;Simone Huygens,&nbsp;Matthijs Versteegh,&nbsp;Maureen Rutten-van Mölken,&nbsp;Rositsa Koleva-Kolarova,&nbsp;Apostolos Tsiachristas,&nbsp;Sarah Wordsworth,&nbsp;Balázs Nagy","doi":"10.2217/pme-2023-0023","DOIUrl":null,"url":null,"abstract":"<p><p>Maturity-onset diabetes of the young (MODY) is often misdiagnosed as Type I or II diabetes. This study was designed to assess the cost-effectiveness of MODY screening strategies in Hungary, which included a recent genetic test compared with no routine screening for MODY. A simulation model that combined a decision tree and an individual-level Markov model was constructed to assess the costs per quality-adjusted life year of screening strategies. Stratifying patients based on age and insulin treatment followed by a risk assessment questionnaire, a laboratory test and genetic testing was the most cost-effective strategy, saving EUR 12 and generating 0.0047 quality-adjusted life years gained per screened patient. This screening strategy could be considered for reimbursement, especially in countries with limited resources.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":"375-385"},"PeriodicalIF":1.7000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2023-0023","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 2

Abstract

Maturity-onset diabetes of the young (MODY) is often misdiagnosed as Type I or II diabetes. This study was designed to assess the cost-effectiveness of MODY screening strategies in Hungary, which included a recent genetic test compared with no routine screening for MODY. A simulation model that combined a decision tree and an individual-level Markov model was constructed to assess the costs per quality-adjusted life year of screening strategies. Stratifying patients based on age and insulin treatment followed by a risk assessment questionnaire, a laboratory test and genetic testing was the most cost-effective strategy, saving EUR 12 and generating 0.0047 quality-adjusted life years gained per screened patient. This screening strategy could be considered for reimbursement, especially in countries with limited resources.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于基因的筛查策略对年轻人成熟期糖尿病的成本效益。
青年期成熟期糖尿病(MODY)常被误诊为I型或II型糖尿病。这项研究旨在评估匈牙利MODY筛查策略的成本效益,其中包括最近的一项基因测试,与没有常规筛查的MODY相比。构建了一个结合决策树和个体水平马尔可夫模型的模拟模型,以评估筛选策略的每个质量调整生命年的成本。根据年龄和胰岛素治疗对患者进行分层,然后进行风险评估问卷、实验室检测和基因检测,这是最具成本效益的策略,为每位筛查患者节省了12欧元,并增加了0.0047个质量调整后的生命年数。可以考虑采用这种筛选策略进行补偿,特别是在资源有限的国家。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Personalized medicine
Personalized medicine 医学-药学
CiteScore
3.30
自引率
4.30%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
期刊最新文献
Challenges and opportunities in building a health economic framework for personalized medicine in oncology. Developing and validating noninvasive prenatal testing for de novo autosomal dominant monogenic diseases in Vietnam. Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems. Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1